Lymphoid enhancer-binding factor 1 (LEF-1): a favorable prognostic factor in adult acute myeloid leukemia in Egyptian patients

Egyptian Journal of Medical Human Genetics

Table 1 Cytogenetic classification and response to therapy at day 28 after induction therapy for AML patients

Parameters		Patients
Parameters		N	%
Cytogenetics	Normal karyotype	15	50.0%
	t(15;17) (q22;q12)	5	16.7%
	t(8,21) (q22;q22)	4	13.3%
	inv 16 (p13q22)	1	3.3%
	11q23 rearrangement	2	6.7%
	Monosomy 7	1	3.3%
	t(9,22) (q34;q11)	1	3.3%
	Trisomy 8	1	3.3%
Cytogenetics classification*	Poor	4	13.3%
	Intermediate	16	53.3%
	Good	10	33.3%
Response to therapy at day 28	Hematological remission	9	30.0 %
	Incomplete remission	13	43.3 %
	Died	8	26.7 %

*Patients were classified as good, poor, and intermediate cytogenetic prognostic groups according to cytogenetic analysis where t(8;21) (q22;q22), inv16 (p13;q22), and t(15;17) (q22;q21) were considered as good prognosis, while normal karyotype and trisomy 8 were considered intermediate prognosis, and 11q23 rearrangement, monosomy 7, t(9,22) (q34;q11) were considered poor prognosis by Wang and Bailey [17]